Literature DB >> 30807526

Sparstolonin B: A Unique Anti-Inflammatory Agent.

Natesh Yepuri1, Ravi Dhawan, Mitchell Cooney, Napat Pruekprasert, Qinghe Meng, Robert N Cooney.   

Abstract

Toll-like receptors are transmembrane proteins which sense and transmit infectious and inflammatory responses to the cells expressing them. Therapeutic strategies for the blockade of excessive Toll-like receptor signaling are being actively pursued for several diseases. Recently, Sparstolonin B, isolated from Chinese herb, which suppresses selectively Toll-like receptors has been studied in various inflammatory models. The objective of this review is to summarize the current literature regarding the use of Sparstolonin B in various in vitro and in vivo studies and to provide an overview regarding the potential use of this agent in different inflammatory diseases. Additionally, the current knowledge regarding the role of Toll-like receptors in inflammatory disease and the usage of various Toll-like receptor antagonists will be summarized. Based on our review, we believe Sparstolonin B could serve as a potential therapeutic agent for treatment of Toll-like receptor-mediated inflammatory disorders.

Entities:  

Year:  2019        PMID: 30807526     DOI: 10.1097/SHK.0000000000001326

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  3 in total

1.  What's New in Shock, December 2019?

Authors:  Russell B Hawkins; Philip A Efron; Shawn D Larson
Journal:  Shock       Date:  2019-12       Impact factor: 3.454

2.  Exploration of the Modulatory Property Mechanism of ELeng Capsule in the Treatment of Endometriosis Using Transcriptomics Combined With Systems Network Pharmacology.

Authors:  Weilin Zheng; Jie Wang; Jiayi Wu; Tao Wang; Yangxue Huang; Xuefang Liang; Lixing Cao
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

3.  Effects of Sparganii Rhizoma on Osteoclast Formation and Osteoblast Differentiation and on an OVX-Induced Bone Loss Model.

Authors:  Sungyub Lee; Minsun Kim; Sooyeon Hong; Eom Ji Kim; Jae-Hyun Kim; Youngjoo Sohn; Hyuk-Sang Jung
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.